Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Capecitabine × 90 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Stomach Neoplasms 17 Rectal Neoplasms 14 Colorectal Neoplasms 13 Triple Negative Breast Neoplasms 10 Neoplasm Metastasis 10 Adenocarcinoma Of Esophagus 7 Esophageal Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Nasopharyngeal Carcinoma 5 Colonic Neoplasms 5 Adenocarcinoma 5 Recurrence 4 Neoplasms 4 Cholangiocarcinoma 4 Locally Advanced Rectal Cancer 3 Colorectal Cancer Metastatic 3 Brain Neoplasms 3 Anus Neoplasms 3 Somatostatinoma 2 Pathologic Complete Response 2 HER2-positive Gastric Cancer 2 Gallbladder Neoplasms 2 Biliary Tract Neoplasms 2 Bile Duct Neoplasms 2 Advanced Solid Tumour 2 Solid Cancer 1 Resectable Colon Cancer 1 Rectal Neoplasms Malignant 1 Pancreatic Neoplasms 1

Interventions

pertuzumab 2 Trastuzumab 2 tucatinib 1 pyrotinib 1 Paclitaxel 1 Fluorodeoxyglucose F18 1 Docetaxel 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡